Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014;10(10):2983-91.
doi: 10.4161/hv.29944.

Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China

Yuanxi Jia  1 , Li Li, Fuqiang Cui, Dongliang Zhang, Guomin Zhang, Fuzhen Wang, Xiaohong Gong, Hui Zheng, Zhenhua Wu, Ning Miao, Xiaojin Sun, Li Zhang, Jingjing Lv, Feng Yang
Affiliations

Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China

Yuanxi Jia et al. Hum Vaccin Immunother. 2014.

Abstract

Objective: The aim of the study was to estimate long-term cost‑effectiveness of a hepatitis B vaccination catch-up program among children born between 1994 and 2001 (when they were 8‑15 y old) in Shandong province, China, to provide information for nationwide evaluation and future policy making.

Methods: We determined the cost-effectiveness of the catch-up program compared with the status quo (no catch-up program). We combined a Decision Tree model and a Markov model to simulate vaccination and clinical progression after hepatitis B virus (HBV) infection. Parameters in the models were from the literature, a field survey, program files, and the National Notifiable Disease Reporting System (NNDRS). The incremental cost‑effectiveness ratio (ICER) was used to compare the 2 alternative strategies. One-way sensitivity analysis, 2-way sensitivity analysis, and probability sensitivity analysis were used to assess parameter uncertainties.

Results: The catch-up program was dominant compared with the status quo. Using a total of 5.53 million doses of vaccines, the catch-up program could prevent 21,865 cases of symptomatic acute hepatitis B, 3,088 carrier states with positive hepatitis B surface antigen (HBsAg), and 812 deaths due to HBV infection. The catch-up program could add 28,888 quality-adjusted life years (QALYs) and save $192.01 million in the targeted population in the future. The models were robust, considering parameter uncertainties.

Conclusion: The catch-up program in Shandong province among children born between 1994 and 2001 was 'very cost-saving.' It could save life years and reduce total future costs. Our study supported the desirability and impact of such a catch-up program throughout China.

Keywords: Anti-HBs, Antibody to Hepatitis B Surface Antigen; CC, Compensated Cirrhosis; CHB, Chronic Hepatitis B; Cost-effectiveness Analysis; DC, Decompensated Cirrhosis; GAVI, Global Alliance on Vaccines and Immunization; GDP, Gross Domestic Product; BCR, Benefit-Cost Ratio; HBV, Hepatitis B Virus; HBsAg, Hepatitis B Surface Antigen; HCC, Hepatocellular Carcinoma; HRQoL, Health-Related Quality of Life; HepB3, 3-dose Coverage of Hepatitis B Vaccine; ICER; ICER, Incremental Cost-Effectiveness Ratio; LT-1, the Year of Liver Transplantation; LT-2, Years after Liver Transplantation; MOH, Ministry of Health; NNDRS, National Notifiable Diseases Reporting System; QALY; QALYs, Quality-Adjusted Life Years; catch-up program; hepatitis B virus; vaccination.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The Markov Model.
Figure 2.
Figure 2.
Results of Probabilistic Sensitivity Analysis
See this image and copyright information in PMC

References

    1. Wu B, Li T, Chen H, Shen J. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis. Value Health 2010; 13(5):592-600; PMID:20561341; http://dx.doi.org/ 10.1111/j.1524-4733.2010.00733.x - DOI - PubMed
    1. Qi XQ, Wang Y, Yu JJ. Report on national population hepatitis B sero-epidemiologic survey. Beijing: The People's Medical Publishing House
    1. Averhoff F, Kolwaite A, Ward JW. The role of the GAVI Alliance in improving childhood hepatitis B vaccination in China: Successes, lessons learned, and future global challenges. Vaccine 2013; 31 Suppl 9:J5-7. PMID:23623862 10.1016/j.Vaccine.2013.04.022 - PubMed
    1. Cui FQ, Gong XH, Chen YS. Evaluation on impact of hepatitis B vaccine integrated into routine immunization in the areas of ministry of health/global alliance for vaccine and immunization (gavi) cooperation project P.R. China. Chinese J Vaccines Immun 2009; 15(4):289-93; PMID:20077723 - PubMed
    1. Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). Health Econ 2001; 10(8):751-74; PMID:11747055; http://dx.doi.org/ 10.1111/j.1524-4733.2010.00733.x - DOI - PubMed

Publication types

Substances

LinkOut - more resources